Top

Published in:

Open Access 01-12-2020 | Shock | Review

Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options

Authors: Laurence W. Busse, Nicholas Barker, Christopher Petersen

Published in: Critical Care | Issue 1/2020

Abstract

Vasoplegic syndrome is a common occurrence following cardiothoracic surgery and is characterized as a high-output shock state with poor systemic vascular resistance. The pathophysiology is complex and includes dysregulation of vasodilatory and vasoconstrictive properties of smooth vascular muscle cells. Specific bypass machine and patient factors play key roles in occurrence. Research into treatment of this syndrome is limited and extrapolated primarily from that pertaining to septic shock, but is evolving with the expanded use of catecholamine-sparing agents. Recent reports demonstrate potential benefit in novel treatment options, but large clinical trials are needed to confirm.

Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG, Buffolo E. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg. 1998;39(5):619–23.

Mets B, Michler RE, Delphin ED, Oz MC, Landry DW. Refractory vasodilation after cardiopulmonary bypass for heart transplantation in recipients on combined amiodarone and angiotensin-converting enzyme inhibitor therapy: a role for vasopressin administration. J Cardiothorac Vasc Anesth. 1998;12(3):326–9.PubMed

Byrne JG, Leacche M, Paul S, Mihaljevic T, Rawn JD, Shernan SK, Mudge GH, Stevenson LW. Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation. Eur J Cardiothorac Surg. 2004;25(3):327–32.PubMed

Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation. 2009;120(17):1664–71.PubMed

Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci. 2015;349(1):80–8.PubMed

Shaefi S, Mittel A, Klick J, Evans A, Ivascu NS, Gutsche J, Augoustides JGT. Vasoplegia after cardiovascular procedures-pathophysiology and targeted therapy. J Cardiothorac Vasc Anesth. 2018;32(2):1013–22.PubMed

Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345(8):588–95.PubMed

Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726–34.

Leyh RG, Kofidis T, Struber M, Fischer S, Knobloch K, Wachsmann B, Hagl C, Simon AR, Haverich A. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg. 2003;125(6):1426–31.PubMed

10.

Weis F, Kilger E, Beiras-Fernandez A, Nassau K, Reuter D, Goetz A, Lamm P, Reindl L, Briegel J. Association between vasopressor dependence and early outcome in patients after cardiac surgery. Anaesthesia. 2006;61(10):938–42.PubMed

11.

Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Critical Care (London, England). 2018;22(1):52.PubMedCentral

12.

Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.

13.

Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122–5.PubMed

14.

Jochberger S, Velik-Salchner C, Mayr VD, Luckner G, Wenzel V, Falkensammer G, Ulmer H, Morgenthaler N, Hasibeder W, Dunser MW. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive Care Med. 2009;35(3):489–97.PubMed

15.

Reid IA. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation. 1997;95(5):1108–10.PubMed

16.

Spink J, Cohen J, Evans TJ. The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase. Activation by nuclear factor-kappa B. J Biol Chem. 1995;270(49):29541–7.PubMed

17.

Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997;85(4):766–82.PubMed

18.

Kerbaul F, Guidon C, Lejeune PJ, Mollo M, Mesana T, Gouin F. Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16(1):47–53.PubMed

19.

Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997;112(3):676–92.PubMed

20.

Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR Jr, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116(6):973–80.PubMed

21.

Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000;15(5):347–53.PubMed

22.

Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg. 2001;71(5):1428–32.PubMed

23.

Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Critical Care (London, England). 2018;22(1):174.

24.

Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116(5):1233–9.PubMed

25.

Trager K, Fritzler D, Fischer G, Schroder J, Skrabal C, Liebold A, Reinelt H. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs. 2016;39(3):141–6.PubMed

26.

Jaffer U, Wade RG, Gourlay T. Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth. 2010;2(3):161–75.PubMedPubMedCentral

27.

Atan R, Crosbie DC, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of human studies. Ren Fail. 2013;35(8):1061–70.PubMed

28.

Anastasiadis K, Antonitsis P, Haidich AB, Argiriadou H, Deliopoulos A, Papakonstantinou C. Use of minimal extracorporeal circulation improves outcome after heart surgery; a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2013;164(2):158–69.PubMed

29.

Landis RC, Brown JR, Fitzgerald D, Likosky DS, Shore-Lesserson L, Baker RA, Hammon JW. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. J Extra Corpor Technol. 2014;46(3):197–211.PubMedPubMedCentral

30.

Ranucci M, Balduini A, Ditta A, Boncilli A, Brozzi S. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg. 2009;87(4):1311–9.PubMed

31.

De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–89.PubMed

32.

Ducrocq N, Kimmoun A, Furmaniuk A, Hekalo Z, Maskali F, Poussier S, Marie PY, Levy B. Comparison of equipressor doses of norepinephrine, epinephrine, and phenylephrine on septic myocardial dysfunction. Anesthesiology. 2012;116(5):1083–91.PubMed

33.

Egi M, Bellomo R, Langenberg C, Haase M, Haase A, Doolan L, Matalanis G, Seevenayagam S, Buxton B. Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: a systematic literature review. Ann Thorac Surg. 2007;83(2):715–23.PubMed

34.

Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaiotto FA, et al. Vasopressin versus norepinephrine in patients with Vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology. 2017;126(1):85–93.PubMed

35.

Hartmann C, Radermacher P, Wepler M, Nussbaum B. Non-Hemodynamic Effects of Catecholamines. Shock (Augusta, Ga). 2017;48(4):390–400.

36.

Busse LW, Ostermann M. Vasopressor therapy and blood pressure management in the setting of acute kidney injury. Semin Nephrol. 2019;39(5):462–72.PubMed

37.

Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Critical Care (London, England). 2011;15(4):226.

38.

Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am J Med. 1983;74(2):265–71.PubMed

39.

Sehested J, Wacker B, Forssmann WG, Schmitzer E. Natriuresis after cardiopulmonary bypass: relationship to urodilatin, atrial natriuretic factor, antidiuretic hormone, and aldosterone. J Thorac Cardiovasc Surg. 1997;114(4):666–71.PubMed

40.

Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–87.PubMed

41.

Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. Jama. 2016;316(5):509–18.PubMed

42.

McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, Lamontagne F, Healey JS, Whitlock RP, Belley-Cote EP. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. Jama. 2018;319(18):1889–900.PubMedPubMedCentral

43.

Kosmidou I, Chen S, Kappetein AP, Serruys PW, Gersh BJ, Puskas JD, Kandzari DE, Taggart DP, Morice MC, Buszman PE, et al. New-onset atrial fibrillation after PCI or CABG for left main disease: the EXCEL trial. J Am Coll Cardiol. 2018;71(7):739–48.PubMed

44.

Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, Landry DW, Oz MC. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg. 2003;75(3):926–30.PubMed

45.

Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001;27(8):1416–21.PubMed

46.

Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. Jama. 1999;281(15):1415–23.PubMed

47.

Rudyk O, Phinikaridou A, Prysyazhna O, Burgoyne JR, Botnar RM, Eaton P. Protein kinase G oxidation is a major cause of injury during sepsis. Proc Natl Acad Sci U S A. 2013;110(24):9909–13.PubMedPubMedCentral

48.

Parihar A, Parihar MS, Milner S, Bhat S. Oxidative stress and anti-oxidative mobilization in burn injury. Burns. 2008;34(1):6–17.PubMed

49.

Armour J, Tyml K, Lidington D, Wilson JX. Ascorbate prevents microvascular dysfunction in the skeletal muscle of the septic rat. J Applied Physiol (Bethesda, Md : 1985). 2001;90(3):795–803.

50.

Wu F, Wilson JX, Tyml K. Ascorbate protects against impaired arteriolar constriction in sepsis by inhibiting inducible nitric oxide synthase expression. Free Radic Biol Med. 2004;37(8):1282–9.PubMed

51.

Wieruszewski PM, Nei SD, Maltais S, Schaff HV, Wittwer ED. Vitamin C for vasoplegia after cardiopulmonary bypass: a case series. A&A practice. 2018;11(4):96–9.PubMed

52.

Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine--mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther. 2000;68(3):293–303.PubMed

53.

Bailey JM, Makheja AN, Pash J, Verma M. Corticosteroids suppress cyclooxygenase messenger RNA levels and prostanoid synthesis in cultured vascular cells. Biochem Biophys Res Commun. 1988;157(3):1159–63.PubMed

54.

Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A. 1990;87(24):10043–7.PubMedPubMedCentral

55.

Dillon PF, Root-Bernstein RS, Lieder CM. Antioxidant-independent ascorbate enhancement of catecholamine-induced contractions of vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2004;286(6):H2353–60.PubMed

56.

Wilson JX. Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. Biofactors. 2009;35(1):5–13.PubMedPubMedCentral

57.

Han M, Pendem S, Teh SL, Sukumaran DK, Wu F, Wilson JX. Ascorbate protects endothelial barrier function during septic insult: role of protein phosphatase type 2A. Free Radic Biol Med. 2010;48(1):128–35.PubMed

58.

Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229–38.PubMed

59.

Yanase F, Bitker L, Hessels L, Osawa E, Naorungroj T, Cutuli SL, Young PJ, Ritzema J, Hill G, Latimer-Bell C, et al. A pilot, double-blind, randomized, controlled trial of high-dose intravenous vitamin c for vasoplegia after cardiac surgery. J Cardiothoracic Vasc Anesth. 2020;34(2):409–16.

60.

Rodemeister S, Duquesne M, Adolph M, Nohr D, Biesalski HK, Unertl K. Massive and long-lasting decrease in vitamin C plasma levels as a consequence of extracorporeal circulation. Nutrition. 2014;30(6):673–8.PubMed

61.

Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama. 2002;288(7):862–71.PubMed

62.

Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–18.PubMed

63.

Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–24.PubMed

64.

Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. Jama. 2016;316(17):1775–85.PubMed

65.

Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797–808.PubMed

66.

Murphy GS, Whitlock RP, Gutsche JT, Augoustides JG. Steroids for adult cardiac surgery with cardiopulmonary bypass: update on dose and key randomized trials. J Cardiothorac Vasc Anesth. 2013;27(5):1053–9.PubMed

67.

Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;386(10000):1243–53.

68.

Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, Schepp RM, Boer C, Moons KG, van Herwerden LA, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. Jama. 2012;308(17):1761–7.PubMed

69.

Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol Clin Pharmacol. 2010;26(4):517–20.PubMedPubMedCentral

70.

Lenglet S, Mach F, Montecucco F. Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. Expert Rev Cardiovasc Ther. 2011;9(12):1519–25.PubMed

71.

Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kucukarslan N, Gunay C, Demirkilic U, Tatar H. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005;79(5):1615–9.PubMed

72.

Ribeiro NS, N.; Silva, A; Viana, V.; Crvalho, E.: Methylene blue use in coronary artery bypass surgery: a prospective randomized study of the hemodynamic and inflammatory responses. Rev Bras Cir Cardiovasc 2004, 19(1):17–23.

73.

Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analgesia. 2006;103(1):2–8. table of contents

74.

Mehaffey JH, Johnston LE, Hawkins RB, Charles EJ, Yarboro L, Kern JA, Ailawadi G, Kron IL, Ghanta RK. Methylene blue for vasoplegic syndrome after cardiac operation: early administration improves survival. Ann Thorac Surg. 2017;104(1):36–41.PubMedPubMedCentral

75.

Habib AM, Elsherbeny AG, Almehizia RA. Methylene blue for vasoplegic syndrome postcardiac surgery. Indian J Crit Care Med. 2018;22(3):168–73.PubMedPubMedCentral

76.

Shah PR, Reynolds PS, Pal N, Tang D, McCarthy H, Spiess BD. Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series. Can J Anaesth. 2018;65(5):560–8.PubMed

77.

Kruszyna H, Magyar JS, Rochelle LG, Russell MA, Smith RP, Wilcox DE. Spectroscopic studies of nitric oxide (NO) interactions with cobalamins: reaction of NO with superoxocobalamin (III) likely accounts for cobalamin reversal of the biological effects of NO. J Pharmacol Exp Ther. 1998;285(2):665–71.PubMed

78.

Weinberg JB, Chen Y, Jiang N, Beasley BE, Salerno JC, Ghosh DK. Inhibition of nitric oxide synthase by cobalamins and cobinamides. Free Radic Biol Med. 2009;46(12):1626–32.PubMedPubMedCentral

79.

Shapeton AD, Mahmood F, Ortoleva JP. Hydroxocobalamin for the treatment of Vasoplegia: a review of current literature and considerations for use. J Cardiothorac Vasc Anesth. 2019;33(4):894–901.PubMed

80.

Legrand M, Michel T, Daudon M, Benyamina M, Ferry A, Soussi S, Maurel V, Chaussard M, Chaouat M, Mimoun M, et al. Risk of oxalate nephropathy with the use of cyanide antidote hydroxocobalamin in critically ill burn patients. Intensive Care Med. 2016;42(6):1080–1.PubMed

81.

Roderique JD, VanDyck K, Holman B, Tang D, Chui B, Spiess BD. The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg. 2014;97(5):1785–6.PubMed

82.

Klemm SG, C. Abstract 218 - Evaluation Of Hydroxocobalamin In Vasoplegia In Cardiac Surgery. Critical Care Med. 2016;44(12 (Suppl.)):131.

83.

Woehlck HJ, Boettcher BT, Lauer KK, Cronin DC, Hong JC, Zimmerman MA, Kim J, Selim M. Hydroxocobalamin for vasoplegic syndrome in liver transplantation: restoration of blood pressure without vasospasm. A A Case Rep. 2016;7(12):247–50.PubMed

84.

Burnes ML, Boettcher BT, Woehlck HJ, Zundel MT, Iqbal Z, Pagel PS. Hydroxocobalamin as a rescue treatment for refractory vasoplegic syndrome after prolonged cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2017;31(3):1012–4.PubMed

85.

Boettcher BT, Woehlck HJ, Reck SE, Hong JC, Zimmerman MA, Kim J, Zundel MT, Freed JK, Pagel PS. Treatment of vasoplegic syndrome with intravenous hydroxocobalamin during liver transplantation. J Cardiothorac Vasc Anesth. 2017;31(4):1381–4.PubMed

86.

Zundel MT, Feih JT, Rinka JRG, Boettcher BT, Freed JK, Kaiser M, Ghadiali HY, Tawil JN, Woehlck HJ, Pagel PS. Hydroxocobalamin with or without methylene blue may improve fluid balance in critically ill patients with vasoplegic syndrome after cardiac surgery: a report of two cases. J Cardiothorac Vasc Anesth. 2018;32(1):452–7.PubMed

87.

Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004;32(1):1–12.PubMed

88.

Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32(1):21–30.PubMed

89.

Hall A, Busse LW, Ostermann M. Angiotensin in Critical Care. Critical Care (London, England). 2018;22(1):69.

90.

Bussard RL, Busse LW. Angiotensin II: a new therapeutic option for vasodilatory shock. Ther Clin Risk Manag. 2018;14:1287–98.PubMedPubMedCentral

91.

Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of Vasodilatory shock. N Engl J Med. 2017;377(5):419–30.PubMed

92.

Evans A, McCurdy MT, Weiner M, Zaku B, Chow JH. Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome. Ann Thorac Surg. 2019;108(1):e5–7.PubMed

93.

Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED. Synthetic human angiotensin ii for postcardiopulmonary bypass vasoplegic shock. J Cardiothoracic Vasc Anesth. 2019;33(11):3080–84.

94.

Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, Miller RR 3rd, Hirshberg EL, Grissom CK, Morris AH. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013;143(3):664–71.PubMed

95.

Sviri S, Hashoul J, Stav I, van Heerden PV. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care. 2014;29(1):157–60.PubMed

96.

Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–8.PubMed

97.

The Society of Thoracic Surgeons Expert Consensus for the Resuscitation of Patients Who Arrest After Cardiac Surgery. Ann Thoracic Surg 2017, 103(3):1005–1020.

98.

Ortoleva JP, Cobey FC. A systematic approach to the treatment of vasoplegia based on recent advances in pharmacotherapy. J Cardiothorac Vasc Anesth. 2019;33(5):1310–4.PubMed

Title: Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options
Authors: Laurence W. Busse
Nicholas Barker
Christopher Petersen
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Shock
Shock
Vasoplegia
Published in: Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-020-2743-8

At a glance: The STEP trials

Springer Medicine

Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

A simple custom appliance against droplet and aerosol transmission of COVID-19 during advanced airway management

Defining persistent critical illness based on growth trajectories in patients with sepsis

Obesity paradox for critically ill patients may be modified by age: a retrospective observational study from one large database

Blocking IL-1 to prevent respiratory failure in COVID-19

Efficacy of ultrasound-guided technique for radial artery catheterization in pediatric populations: a systematic review and meta-analysis of randomized controlled trials

Preventive use of respiratory support after scheduled extubation in critically ill medical patients—a network meta-analysis of randomized controlled trials